tiprankstipranks
Advertisement
Advertisement

NGEN Stock Latest News

NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program
Company AnnouncementsNervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program
4d ago
6K
NGEN
Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors
PremiumCompany Announcements
Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors
7d ago
NGEN
NervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 3
PremiumCompany Announcements
NervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 3
10d ago
6K
NGEN
NervGen Pharma files $250M mixed securities shelf
PremiumThe Fly
NervGen Pharma files $250M mixed securities shelf
10d ago
NGEN
NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291
PremiumThe Fly
NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291
11d ago
NGEN
NervGen Pharma Launches Underwritten Public Offering to Fund NVG-291 Development
PremiumCompany AnnouncementsNervGen Pharma Launches Underwritten Public Offering to Fund NVG-291 Development
14d ago
6K
NGEN
NervGen Pharma 24M share Spot Secondary priced at $2.50
Premium
The Fly
NervGen Pharma 24M share Spot Secondary priced at $2.50
15d ago
NGEN
NervGen Pharma secondary being re-offered at $2.50 per share
Premium
The Fly
NervGen Pharma secondary being re-offered at $2.50 per share
15d ago
NGEN
NervGen Pharma announces common share offering, no amount given
PremiumThe Fly
NervGen Pharma announces common share offering, no amount given
15d ago
NGEN
NervGen Pharma Advances NVG-291 Toward Registrational Trial as Q1 2026 Loss Narrows
PremiumCompany Announcements
NervGen Pharma Advances NVG-291 Toward Registrational Trial as Q1 2026 Loss Narrows
18d ago
6K
NGEN
NervGen Pharma reports Q1 EPS (2c), consensus (7c)
PremiumThe Fly
NervGen Pharma reports Q1 EPS (2c), consensus (7c)
19d ago
NGEN
NervGen Pharma Narrows Quarterly Loss but Cash Reserves Decline in Q1 2026 Filing
PremiumCompany Announcements
NervGen Pharma Narrows Quarterly Loss but Cash Reserves Decline in Q1 2026 Filing
21d ago
6K
NGEN
NervGen Pharma Names New CFO and Wins Shareholder Backing for 2026 Equity Plan
PremiumCompany AnnouncementsNervGen Pharma Names New CFO and Wins Shareholder Backing for 2026 Equity Plan
1M ago
6K
NGEN
NervGen Pharma appoints Keith Vendola as CFO
Premium
The Fly
NervGen Pharma appoints Keith Vendola as CFO
1M ago
NGEN
NervGen Pharma initiated with a Buy at H.C. Wainwright
Premium
The Fly
NervGen Pharma initiated with a Buy at H.C. Wainwright
1M ago
NGEN
NervGen Pharma initiated with a Buy at Lucid Capital
PremiumThe Fly
NervGen Pharma initiated with a Buy at Lucid Capital
2M ago
NGEN
NervGen Pharma price target raised to $12 from $10 at Maxim
PremiumThe Fly
NervGen Pharma price target raised to $12 from $10 at Maxim
2M ago
NGEN
NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia
PremiumCompany Announcements
NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia
2M ago
NGEN
NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting
PremiumThe Fly
NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting
2M ago
NGEN
NervGen Pharma price target lowered to $5.50 from $6.75 at Stifel
PremiumThe FlyNervGen Pharma price target lowered to $5.50 from $6.75 at Stifel
2M ago
NGEN
NervGen Pharma: Buy Rating on De‑Risked Path to Pivotal NVG-291 Trials and Compelling Risk‑Reward in Chronic Spinal Cord Injury
Premium
Ratings
NervGen Pharma: Buy Rating on De‑Risked Path to Pivotal NVG-291 Trials and Compelling Risk‑Reward in Chronic Spinal Cord Injury
2M ago
NGEN
NervGen Maps Path to Phase 3 as NVG-291 Data Strengthen Neuroreparative Ambitions
Premium
Company Announcements
NervGen Maps Path to Phase 3 as NVG-291 Data Strengthen Neuroreparative Ambitions
2M ago
NGEN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >